Minocycline for Acute Stroke: A Systematic Review of Clinical Efficacy, Safety, and Translational Context

Abstract:

Background: Minocycline is a lipophilic, second-generation tetracycline with anti-inflammatory, anti-apoptotic, antioxidant, and matrix metalloproteinase (MMP)-modulating properties. Experimental stroke studies have suggested that these pleiotropic effects can preserve blood–brain barrier integrity, attenuate neuroinflammation, reduce infarct evolution, and potentially mitigate reperfusion-related injury. Earlier clinical studies were small and methodologically heterogeneous, leaving uncertainty about whether minocycline improves patient-important outcomes after acute stroke. The recently reported EMPHASIS trial materially changes the clinical evidence base.

Objective: To systematically review clinical studies evaluating minocycline initiated during the acute phase of stroke, with emphasis on functional outcome, neurological recovery, safety, sources of heterogeneity, and implications for practice and future research.

Methods: A structured evidence synthesis was undertaken using PubMed-indexed literature, major journal databases, ClinicalTrials.gov, and bibliographies of relevant reviews and trials. Eligible studies enrolled adults with acute ischemic stroke (AIS) or intracerebral hemorrhage (ICH) and evaluated systemic minocycline initiated after symptom onset against placebo, usual care, or an active control. Randomized trials, prospective dose-finding studies, and clinical trial protocols/results were included. The principal outcome was 90-day modified Rankin Scale (mRS) outcome. Risk of bias was appraised narratively using RoB 2 domains. Because early trials differed substantially in stroke phenotype, route, dose, comparator, blinding, and outcome reporting, no de novo quantitative meta-analysis was performed.

Results: The evidence evolved from promising open-label studies to one negative intravenous pilot study and, most recently, a large double-blind placebo-controlled trial. Early oral studies reported unusually large benefits but were vulnerable to performance and detection bias. The 95-patient Perth intravenous pilot found no benefit on 90-day mRS 0–2, although minocycline was well tolerated. The EMPHASIS trial randomized 1724 patients with moderate-to-severe AIS within 72 hours and found a higher 90-day rate of mRS 0–1 with minocycline than placebo (52.6% vs 47.4%; adjusted risk ratio 1.11, 95% confidence interval 1.03–1.20; p=0.0061), with a favorable ordinal mRS shift and no evident excess of symptomatic intracranial hemorrhage or serious adverse events. Certainty is now moderate for a modest functional benefit in an EMPHASIS-like population, but external validity remains constrained by geographic concentration, restricted severity range, and the limited evidence in contemporary thrombectomy-treated populations and ICH.

Conclusions: Minocycline is no longer supported only by mechanistic plausibility and small exploratory studies: a large blinded trial shows a modest 90-day functional benefit in AIS without a major safety signal. Nevertheless, one positive phase III trial is insufficient to establish universal routine use. Replication across diverse health systems, rigorous evaluation alongside thrombolysis and thrombectomy, mechanistic biomarker studies, and adequately powered ICH trials are needed before broad guideline adoption.

Keywords: Acute ischemic stroke, minocycline, neuroprotection, neuroinflammation, modified Rankin Scale, systematic review

Continue reading this article...

Enjoying this content? Consider making a donation to help us continue to provide quality medical research at no cost.

Share This Article

Author(s): Adela Bazbaz, Joseph Varon
Published: November 18, 2026
ISSN# 3066-2354

Stay Connected

You'll receive breaking news, updates, and exclusive content.